Notícias e Atividades da Athira Pharma

Athira Pharma é uma empresa listada sob o símbolo ATHA (US).

Veja o organograma con seus 17 executivos principais

Biografias mais buscadas da Athira Pharma

• Mark Litton, President and Chief Executive Officer
• John Fluke, Director
• James Johnson, Director

Criar um alerta
para seguir os movimentos de executivos da Athira Pharma.

Athira Pharma possui 1.832 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Paul Meister - Chairman of the Board da Amneal Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Athira Pharma

• Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND | Athira Pharma
• Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | Athira Pharma
• Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting | Athira Pharma
• Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases | Athira Pharma
• Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease | Athira Pharma
• Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024 | Athira Pharma
• Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates | Athira Pharma
• Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease | Athira Pharma
• Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) | Athira Pharma
• Athira Pharma to Participate in Upcoming June Conferences | Athira Pharma
• View more press releases Close

Redes sociais sobre Athira Pharma

• Athira Pharma na Wikipedia, Google News e Yahoo Finance
• Athira Pharma na LinkedIn, Twitter e YouTube